

**WILMER CUTLER PICKERING  
HALE AND DORR LLP****Via Facsimile (571) 273-0844**

September 22, 2004

Examiner Phillip Gambel  
Primary Examiner  
Art Unit 1644  
United States Patent and Trademark Office

Re: U.S. Serial No. 09/350,202  
*Methods for Selectively Stimulating Proliferation of T cells*  
Atty. Docket No.: 36119.125US9

Dear Phil:

Further to your telephone message of September 20, 2004, please find attached a Second Supplemental Amendment and Response in the above-referenced application. I have faxed you a copy of the Supplemental Amendment, per your request, to expedite prosecution of this case.

***Please enter this Supplemental Amendment and Response into the official file for the above-referenced application.***

If you should have any questions regarding this matter, please do not hesitate to contact me.

Sincerely,



Colleen Superko

JJK:srm  
Attachment

Colleen Superko

60 STATE STREET  
BOSTON, MA 02109  
+1 617 526 6564  
+1 617 526 5000 fax  
colleen.superko@wilmerhale.com

BALTIMORE BERLIN BOSTON BRUSSELS LONDON MUNICH  
NEW YORK NORTHERN VIRGINIA OXFORD PRINCETON WALTHAM WASHINGTON

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.	09/350,202	Art Unit	1644
Applicant:	June <i>et al.</i>	Examiner:	Phillip Gambel
Date Filed:	July 8, 1999	Conf. No.	7708
Docket No.	36119.125US9	Cust. No.	23483
Title:	Methods for Selectively Stimulating Proliferation of T Cells		

CERTIFICATION UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence is being transmitted via facsimile to Examiner Phillip Gambel at the United States Patent and Trademark Office at (571) 273-0844.

9/22/04  
Date of Transmission

*Rochelle Capobianco*  
Rochelle Capobianco

SECOND SUPPLEMENTAL AMENDMENT AND RESPONSE  
PURSUANT TO 37 C.F.R. § 1.116

Sir:

In further response to the Final Office Action dated *April 13, 2004*, the Amendment and Response filed July 27, 2004, and the Supplemental Amendment and Response filed August 13, 2004, Applicants respectfully request that the above-referenced application be reconsidered in light of the following:

A Listing of the Pending Claims is presented on *page 2* of this paper.

Remarks begin on *page 5* of this paper.

Appendix A including a Terminal Disclaimer is attached following *page 7* of this paper.